A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.

A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.

Item
http://www.wikidata.org/entity/Q34818301
Recent advances in the use of PI3K inhibitors for glioblastoma multiforme: current preclinical and clinical developmentMetabolomics of Therapy Response in Preclinical Glioblastoma: A Multi-Slice MRSI-Based Volumetric Analysis for Noninvasive Assessment of Temozolomide TreatmentInhibition of glioblastoma dispersal by the MEK inhibitor PD0325901.BKM-120 (Buparlisib): A Phosphatidyl-Inositol-3 Kinase Inhibitor with Anti-Invasive Properties in Glioblastoma.Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.Creation of an NCI comparative brain tumor consortium: informing the translation of new knowledge from canine to human brain tumor patients.Brain Tumor Diagnostics and Therapeutics with Superparamagnetic Ferrite Nanoparticles.The impact of P-glycoprotein and breast cancer resistance protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma.Development of a transplantable glioma tumour model from genetically engineered mice: MRI/MRS/MRSI characterisation.MRSI-based molecular imaging of therapy response to temozolomide in preclinical glioblastoma using source analysis.PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition
P2860

A preclinical orthotopic model for glioblastoma recapitulates key features of human tumors and demonstrates sensitivity to a combination of MEK and PI3K pathway inhibitors.

Item
http://www.wikidata.org/entity/Q34818301
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@ast
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@en
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@nl
type
label
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@ast
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@en
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@nl
prefLabel
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@ast
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@en
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932
P356
P1433
P1476
A preclinical orthotopic model ...... K and PI3K pathway inhibitors.
@en
P2093
P2860
P304
P31
P356
P433
P478
P577
P5875
P698
P932